IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

Journal of Immunotherapy

Volumn 29, Issue 3, 2006, Pages 313-319

  Rosenberg, Steven A ^a   Sportès, Claude ^a   Ahmadzadeh, Mojgan ^a   Fry, Terry J ^a   Ngo, Lien T ^a   Schwarz, Susan L ^a   Stetler Stevenson, Maryalice ^a   Morton, Kathleen E ^a   Mavroukakis, Sharon A ^a   Morre, Michel ^b   Buffet, Renaud ^b   Mackall, Crystal L ^a   Gress, Ronald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Cytheris   (France)

Author keywords

Human lymphocytes; Interleukin 7; Lymphopoiesis; Regulatory T cells

Indexed keywords

INTERLEUKIN 7; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 7; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPOIESIS; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; SARCOMA; AGED; BONE MARROW; BONE MARROW CELL; CELL PROLIFERATION; CLINICAL TRIAL; LYMPHOPOIESIS; METABOLISM; MIDDLE AGED;

ADULT; AGED; BONE MARROW; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-7; LYMPHOPOIESIS; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 33746046073     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1080/03601270600564088     Document Type: Article

References (22)

1. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892-3904.
2. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
3. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180:1955-1960.
4. Morrissey PJ, Conlon P, Braddy S, et al. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol. 1991;146:1547-1552.
5. Talmadge JE, Jackson JD, Kelsey L, et al. T-cell reconstitution by molecular, phenotypic, and functional analysis in the thymus, bone marrow, spleen, and blood following split-dose polychemotherapy and therapeutic activity for metastatic breast cancer in mice. J Immunother. 1993;14:258-268.
6. El Kassar N, Lucas PJ, Klug D, et al. A dose effect of IL-7 on thymocyte development. Blood. 2004;104:1419-1427.
7. Chu Y, Memon S, Sharrow S, et al. TCR Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhancing thymic function. Blood. 2004;104:1110-1119.
8. Fisher AG, Burdet C, Bunce C, et al. Lymphoproliferative disorders in IL-7 transgenic mice: expansion of immature B cells which retain macrophage potential. Int Immunol. 1995;7:415-423.
9. Samaridis J, Casorati G, Traunecker A, et al. Development of lymphocytes in interleukin 7-transgenic mice. Eur J Immunol. 1991;21:453-460.
10. Yeoman H, Clark DR, DeLuca D. Development of CD4 and CD8 single positive T cells in human thymus organ culture: IL-7 promotes human T cell production by supporting immature T cells. Dev Comp Immunol. 1996;20:241-263.
11. Puel A, Ziegler SF, Buckley RH, et al. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20:394-397.
12. Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood. 2003;101:2294-2299.
13. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
14. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
15. Bakke AC, Purtzer MZ, Wildin RS. Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). Clin Exp Immunol. 2004;137:373-378.
16. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74:961-965.
17. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409-2414.
18. + regulatory T cells. Nat Med. 2005;11:1238-1243.
19. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med. 1995;332:567-575.
20. + T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005;115:1839-1847.
21. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
22. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.